Nanjing Leads Biolabs Secures Nearly RMB 100 Million in New Funding to Accelerate Clinical Development of Antibody Therapeutics

VCBeat (biobeat1) has learned that Nanjing Leadsbiolabs Co., Ltd. (hereinafter referred to as “Leads Biolabs”) has recently successfully completed a new round of financing amounting to nearly RMB 100 million. This round was jointly funded by existing investors, including Shanghai Jianxin Capital, Enran Venture Capital, and Chongshan Capital, as well as new investors such as Huafang Capital and Hygeia Capital. The proceeds from this financing will be used to rapidly advance the company’s existing novel antibody drug products into the clinical research stage, while also promoting preclinical studies for other projects in development and expanding its new R&D pipeline.

Leads Biolabs, established in 2012 and headquartered in Nanjing, Jiangsu Province, is a biopharmaceutical company dedicated to the research and development of novel antibody-based therapeutics with independent intellectual property rights for the treatment of cancer and other major diseases. Leads Biolabs focuses on addressing unmet medical needs, particularly the challenges and issues facing cancer immunotherapy.

Previously, Leads Biolabs completed two rounds of financing in 2015 and 2017. Leveraging its technological platforms for the development of novel drugs based on single-target antibodies and bispecific antibodies, the company has established a robust R&D pipeline comprising more than ten novel tumor immunotherapy antibody projects, garnering strong support from both existing and new investors.

Shanghai Jianxin Capital is a venture capital fund focused on the biopharmaceutical industry. The company concentrates on major diseases and significant clinical needs, conducts in-depth research, and proactively invests in startups with top-tier teams and technological platforms. It provides professional insights, experience, and resources in areas such as product pipeline development, team building, regulatory filing and registration, clinical trials, and commercial partnerships, aiming to accelerate their growth into industry leaders. Yuan Quanhong, President of Shanghai Jianxin Capital, stated, “Leads Biolabs has strategically positioned itself in the field of tumor immunotherapy, establishing a robust pipeline of next-generation immunotherapeutic antibodies. The company is advancing its products into clinical stages at a leading pace domestically. We are honored to participate in the investment in Leads Biolabs and will fully support its growth into an industry leader in the field of next-generation immunotherapy.”

Regarding this financing round, Dr. Kang Xiaoqiang, Founder, Chairman, and General Manager of Leads Biolabs, stated, “We are deeply grateful to both new and existing shareholders for their strong trust and significant support in Leads Biolabs, as well as for their high recognition of our biotechnology platform and product pipeline. The proceeds from this financing will be primarily used to advance product development and clinical trials, while also attracting and cultivating top-tier pharmaceutical talent. This will help Leads Biolabs seize opportunities, drive innovation, and develop high-quality novel antibody drugs.”